Lipid peroxidation, a general mechanism of tissue damage by free radicals, damages cells and may induce pathological events [1] . Analytical tests to assess lipid peroxidation include the following techniques: fluorometry of lipofuscin-like substances in serum [2] ; spectrophotometry of conjugated dienes in lipid extracts of plasma and microsomes [3, 4] ; gas chromatography of ethane or pentane in exhaled breath [5] ; hydroperoxide determination [6] ; malondialdehyde (MDA) evaluation with or without thiobarbituric acid (TBA) reaction and spectrophotometry [7] , fluorometry [8] , and high-performance liquid [9, 10] or gas-liquid [11, 12] chromatographies; measurements of other saturated and unsaturated aldehydes [13] ; and oxygen uptake during lipid peroxidation [14] .
The most widely used method is the TBA reaction with MDA. This method is of particular interest because of its procedural simplicity and nanomolar sensitivity. However, its specificity has been questioned [10 -16] , and it overestimates MDA [17] [18] [19] [20] [21] . We describe a method to measure free MDA with use of high-performance capillary electrophoresis (HPCE).
We used a Waters Quanta-4000 Capillary System with UV detection at 280 nm, AUFD 0.002, mercury lamp, phosphor window and cElect-P175 (Supelco) neutral hydrophilic phase capillary (75 m x 60 cm). Buffer with 10 mmol/L sodium tetraborate, 10 mmol/L sodium monophosphate (Sigma Chemical Co.), pH 8.0, with 100 mL/L acetonitrile (analytical grade, Fisher Scientific) was filtered with a 0.45-m filter; running voltage was ϩ18 kV. Samples were injected hydrostatically in 10 s. Data were recorded on a Waters-746 integrator.
In accordance with patients' written consent and the ethical standards of Long Island Jewish Medical Center's Human Subjects Review Committee (exemption no. B5), blood from patients undergoing cardiopulmonary bypass surgery was collected by venipuncture or from the arterial line into Vacutainer Tubes containing heparin (Becton Dickinson) and 25 L of 100 g/L butylated hydroxytoluene (Sigma) in ethanol. Samples were centrifuged at 1200g for 10 min at 4°C. Plasma was either analyzed within 2 h or frozen at Ϫ20°C.
Calibrators: MDA was prepared by hydrolysis of 1,1,3,3-tetraethoxypropane (Sigma) in 4 mmol/L HCl (Fisher Scientific) for 1 h at 50°C. The concentrations of working calibrators (800 -1000 mol/L) were calculated from the molar absorptivity (⑀ ϭ 31 800 mol Ϫ1 cm
Ϫ1
) at 267 nm.
Sample preparation: Heparinized plasma (0.5 mL) was added to 1 mL of pure acetonitrile (ice cold), vortexmixed, kept at 4°C for 5 min, and centrifuged at 16 000g at 4°C for 15 min. The supernatant was removed and filtered (0.22-m pore size). The filtrate (600 L) was pipetted into the carousel sample vials and injected. All reagents were stored at 4°C and protected from light.
TBA assay: Heparinized plasma (0.5 mL); 1 mL of TBA, 3.7 g/L (Sigma) in 0.25 mol/L HCl; and 3 mL of 15% trichloroacetic acid (Sigma) in 0.25 mol/L HCl were combined in a 12-mL screw-cap Pyrex centrifuge tube, mixed, and heated for 30 min in boiling water. After cooling in an ice bath, 6 mL of n-butanol (analytical grade, Sigma) was added and the chromogen extracted. The absorbance of the organic phase was determined at 535 nm against a blank.
LPO-586 assay (patented method): Reagent R1 (0.650 mL; chromogenic reagent, Bioxytech) was poured into a 6-mL Pyrex test tube. Heparinized plasma (0.2 mL) was added and the mixture was vortex-mixed. The reaction was started by adding 0.15 mL of reagent R2 (10.4 mol/L methanesulfonic acid, Bioxytech), mixing, and incubating at 45°C for 40 min. The reaction mixture was cooled to room temperature and the absorbance determined at 586 nm.
Imprecision: The precision of the method was determined by running samples of plasma (n ϭ 6) in duplicate supplemented with 10 -30 mol/L and 30 -50 mol/L MDA from day to day for 5 days. The CV was 4.24% and 3.48%, respectively. The mean CV was 3.86% for concentration range 10 -50 mol/L MDA. The method was linear from 0 -1.26 pmol injected (r ϭ 0.9932). The mass limit of detection for MDA in buffer was 0.08 pmol and for MDA added to plasma 0.126 pmol, corresponding to a plasma concentration of 12.6 mol/L. Recovery of MDA added to plasma before deproteinization with acetonitrile was 89 -95%, n ϭ 6, at 12.6 pmol. Table 1 . Plasma MDA in patients undergoing CABG as determined by TBA, LPO-586, and HPCE methods. 
Technical Briefs
We measured the MDA concentrations in plasma of patients undergoing coronary artery bypass grafting (CABG) by the TBA assay and by use of a commercially available lipid peroxidation kit (LPO-586, Bioxytech) and by HPCE. MDA was undetectable by HPCE ( Table 1) .
The so-called TBA test is notoriously nonspecific and the fact that it is assayed under a strong acidic condition at an increased temperature suggests the possibility of generating MDA artifactually during analysis. Because of the artifactual production of TBA-reactive substances, the values estimated with the TBA assay of patients undergoing CABG were most likely due to the presence of a color-producing substance other than free MDA.
Autoxidation of unoxidized lipids and generation of MDA-like compounds during sample processing are among the most critical and confounding factors limiting the measurement of MDA. In a biological matrix the assay is further complicated by the nature of the peroxide intermediates generated during heating, and their reactivity with other components by the presence of MDAlike compounds. Furthermore, the nonspecificity of the MDA-TBA test does not allow measurement of low concentrations of MDA in normal tissue (except in rat liver microsomes) or plasma. Also, the bulk of the MDA-TBA complexes are nonvolatile and most likely produced by decomposition of lipid peroxide during heating at higher temperature. Iron contamination of the TBA reagents may also cause an increase in lipid peroxidation. The relatively high amounts of MDA-TBA complexes in plasma may also be related to compounds other than MDA, namely bile pigments, unsaturated aldehydes, sugars, and amino acids, that react with TBA and absorb at 532 nm. In human plasma the TBA reaction also measures endoperoxides. However, the mean endoperoxide concentration measured by the enzymatic method was found to be 0.5 mol/L, whereas TBA gave 38 mol/L [17] .
With our HPCE method we found no free MDA in the plasma of CABG patients but a considerable amount of MDA-TBA activity (Fig. 1) . The absence of MDA in CABG patients is not surprising considering the tendency of MDA to form a complex with proteins and amino acids and its rapid enzymatic degradation by the liver aldehyde dehydrogenase. Reported increased concentrations of MDA in diverse pathological conditions should be interpreted with caution because of the formation of TBAreactive substances present in plasma.
In conclusion, the electrophoretic separation and quantification of MDA in human plasma by HPCE has proven to be direct, rapid, sensitive (0.08 pmol), and reproducible (2%). There was little effect of electroosmotic flow (EOF) in the migration time of MDA in supplemented plasma samples. By using the cElect-P175 hydrophilic phase coated capillary, separation and detection were optimized with minor effect of EOF at pH 8.0, and the high molar absorptivity of MDA, 267 nm, at neutral or alkaline pH permits adequate sensitivity at 280 nm with a fixed wavelength detector. This HPCE method developed by us is very specific when compared with the TBA and LPO-586 assays and much more sensitive (10ϫ) than the HPLC method. Extreme caution should be taken when interpreting plasma MDA data obtained with the TBA and LPO-586 assays, and a more valid technique such as HPLC or HPCE should be used to quantify these concentrations in human plasma. [1] . Apo E binds to the LDL receptor, also termed the B,E receptor, because the receptor accepts both apo B and apo E. Apo E is also thought to bind to a specific chylomicron remnant receptor by virtue of its structural determinants. The heterogeneity in receptor binding of different varieties of apo E is explained by the affinity of different apo E alleles to various receptors. Apo E polymorphisms may be explained by three major alleles: apo E⑀2, apo E⑀3, and apo E⑀4, which are found in 10%, 76%, and 13%, respectively, of the Caucasian population [2] . The polymorphisms are due to substitution of a cysteine for an arginine at residue 112 or 158, or at both residues. The apo E⑀2 variant has the lowest affinity for the LDL receptor.
There is an LDL concentration gradient in both the healthy population and in those with coronary heart disease. Individuals homozygous for apo E⑀2 have the lowest concentrations of LDL, and apo E⑀4 homozygotes have the highest LDL concentrations [3] . The apo E⑀4 allele has also been associated with Alzheimer disease. However, the mechanisms of this association are not yet clear [4] . Thus, the interest in apo E polymorphisms is high, both on the basis of epidemiological research and for the purpose of clarifying individual lipid disturbances or dementias. We have successfully applied the oligonucleotide ligation assay (OLA) technique to screen for mutations causing familial hypercholesterolemia [5] . We have now adapted this technique for the detection of apo E polymorphisms in large numbers of samples.
PCR amplification of genomic DNA from peripheral blood was performed in a Perkin-Elmer 9600 Thermocycler. A 310-bp fragment of the apo E gene was amplified with the following primer sequences: 5Ј-GAG ACG CGG GCA CGG CTG TC-3Ј(upper primer) and 5Ј-GCA CGC GGC CCT GTT CCA C-3Ј(lower primer). The PCR reactions were performed in a total volume of 20 L containing 10 mmol/L Tris-HCl pH 8
ng of genomic DNA, and 0.6 U of AmpliTaq Gold DNA polymerase (Applied Biosystems Division of PerkinElmer). Amplification conditions consisted of an initial 10-min denaturation at 95°C followed by 40 cycles of 94°C for 30 s, 68°C for 30 s, 72°C for 1 min, and a final extension of 5 min at 72°C. An 8-L aliquot of PCR product was used for OLA analysis.
The ethylene oxide mobility modifier chemistry was chosen because of several desirable properties [6] . The probes are characteristically hydrophilic as required for a solution-phase enzymatic reaction. In addition, they are nonnucleotidic and partially negatively charged, to minimize potential nonspecific interactions with the oligonucleotide portion of the probe or with the target DNA. As a consequence, the mobility-modifying tails affect the T m of the probes very little. The synthesis of this type of probe can be accomplished efficiently by using standard automated DNA synthesis chemistry [7, 8] . We have found it best to use pentaethyleneoxide (PEO) modifiers, because the corresponding phosphoramidite monomers can be synthesized more effectively than the hexaethyleneoxide monomers (David G. Sherman, Applied Biosystems, personal communication).
OLA reactions for two polymorphic sites, located in the apo E gene, were multiplexed in one tube. Three synthetic oligonucleotide probes were used for the analysis of each polymorphic site, two allelic probes with 5Ј-PEO tails of different length, and one common, 3Ј-fluorescently labeled reporter probe. The sequences of the probes and the numbers of mobility modifiers are given in Table 1. OLA  reactions were A 2-L aliquot of each multiplex OLA product was mixed with 2.5 L of deionized formamide, 0.5 L of dextran blue loading buffer, and 0.5 L of Genescan-500 Tamra size marker. The mixture was denatured at 95°C for 3 min and then rapidly cooled on ice before loading the gel. OLA products were electrophoresed for 2.5 h at 2500 V on an automated Model 373A fluorescence-scanning DNA sequencer (Applied Biosystems Division of Perkin-Elmer) with an 8% acrylamide, 19:1 acrylamide: bisacrylamide denaturing gel containing 8.3 mol/L urea, 89 mmol/L Tris, 89 mmol/L boric acid, and 2 mmol/L EDTA. The gel thickness was 0.4 mm and the well-to-read length was 24 cm. The resulting gel data were analyzed for peak color and fragment size by using the Genescan 672 fragment analysis software and the Genotyper software (Applied Biosystems Division of Perkin-Elmer). Figure 1 shows OLA results from six probands with the six possible apo E genotypes. After PCR amplification of the apo E gene fragment that contains the two polymorphic sites of interest, competitive OLA is run at both loci. For each polymorphic site, two allele-specific oligonucleotide probes and a third, common probe are hybridized to one strand of the PCR product such that the 3Ј ends of the allele-specific probes are immediately adjacent to the 5Ј end of the common probe. This sets up a competitive hybridization-ligation process between the two allelic probes and the common probe. The thermostable DNA ligase then discriminates between single-base mismatches at the junction site [9] , thereby producing allele-specific ligation products. Since the common probe is labeled with a fluorescent dye and the allele-specific probes are linked to different-length PEO mobility-modifying tails, each ligation product can be identified by its defined electrophoretic mobility and fluorescent color on a four-color fluorescence-scanning sequencer. The mobility modifiers allow the mobility of each ligation product to be arbitrarily defined, regardless of oligonucleotide length or sequence. They are oligomeric, making them suitable for assembly onto the probes during automated oligonucleotide synthesis. This approach to multiplex analysis is termed "sequence-coded separation" to highlight both the decoupling of mobility from the physical size of the ligated probe and the deliberately designed linkage between mobility and target sequence [6] . The sequences of the oligonucleotides we used and the ligation product sizes are given in Table 1 .
After gel electrophoresis is completed, the Genescan and Genotyper software are used to analyze the gel data. Lanes are defined and fragments are sized. The probands had been genotyped with conventional methods earlier.
The results were the same in every instance, assuring the desired sensitivity and specificity of the method. In addition to a global quality check, the entire analysis, namely sizing, allele calling, and reporting, is automated. The results are automatically compiled and transferred by computer to our computerized clinical data base. This approach allows correlations to be drawn with the clinical findings, which allows the clinician to make reasoned judgments regarding clinical care.
Our data demonstrate the utility and power of the OLA technology in identifying apo E polymorphisms. PCRbased procedures have been used by others to identify the underlying mutations in apo E [3, 4] . The OLA approach facilitates our diagnostic capabilities above and beyond the earlier methodology. The new method is sensitive, specific, reproducible, fast, and flexible [5] . The OLA technique will permit epidemiologists to determine the frequency and heterogeneity of apo E mutations in population studies.
The OLA assay can be done quickly because of the single tube and single gel lane format. Furthermore, the Genotyper software method makes the OLA objective and independent from interference by users. Thus, quality control can be easily determined, which simplifies the application of this method for clinical care.
We have adapted the OLA method to the point that blood sampling can be accomplished with a few drops of blood onto filter paper or even from a salivary sample [10, 11] . Thus, the samples can be shipped through the mail inside a simple envelope. This feature makes the OLA particularly attractive for large-scale epidemiological investigations and studies in population genetics. Obviously, a strategy must be applied that takes into consideration informed consent and rights of privacy. We have developed such approaches (unpublished).
Interest in apo E polymorphisms has recently increased greatly because of the association of apo E⑀4 with Alzheimer disease. Heart disease is increased in patients with Alzheimer disease and the increased occurrence of both diseases has been linked to the presence of the apo E⑀4. The enzyme Na ϩ /K ϩ -ATPase (EC 3.6.1.37) plays a central role in the regulation of intra-and extracellular cation homeostasis. Alteration of this transport enzyme is thought to be linked to several diseases (including cardiovascular disorders, hypertension, and diabetes mellitus) [1] . However, measurement of Na ϩ /K ϩ -ATPase activity is not widespread, partly because of the lack of a method with a low detection limit available for the general clinical laboratory. For this purpose we have applied the determination of Na ϩ /K ϩ -ATPase activity to a Hitachi 704 automated analyzer. Our method is based on an ATPregenerating system ( Fig. 1) , where the linear rate of NADH oxidation correlates to the hydrolysis of ATP [2] . One unit (1 U) of ATPase represents 1 mol of NADH oxidation per minute.
For the estimation of precision and linearity, EDTA-K 2 anticoagulated blood samples of healthy volunteers were hemolyzed (1:15) in 10 mmol/L Tris-HCl (pH 7.6), 1 mmol/L EDTA, and washed four times at 12 000g (4°C) with the same solution. The protein content of hemoglobin-free pellets (ghosts) was determined according to Each apo E allele is specified by an individual combination of two OLA products, resulting from allele-specific ligation at the two polymorphic DNA positions.
Bradford [3] , with bovine serum albumin as a calibrator. Ghosts were diluted to protein contents of 0.5, 1, 1.5, 2, and 2.5 g/L. The samples with protein contents of 0.5 g/L (low activity), 1.5 g/L (medium activity), and 2.5 g/L (high activity) were divided into aliquots and stored at Ϫ80°C until the measurements.
Samples (20 L) were added to 380 L of Reagent 1 (final concentration per liter: 100 mmol of NaCl, 20 mmol of KCl, 2.5 mmol of MgCl 2 , 0.5 mmol of EGTA, 50 mmol of TrisHCl, pH 7.4, 1.0 mmol of ATP, 1.0 mmol of phosphoenolpyruvate, 0.16 mmol of NADH, 5 kU of pyruvate kinase, 12 kU of lactate dehydrogenase; all from Sigma). After 300 s, 5 L of 10 mmol/L ouabain (Reagent 2) was added to inhibit the ouabain-sensitive ATPase activity. The change in absorbance was monitored at 340 nm (reference wavelength 415 nm) by a twin test (i.e., combination of two assays in one cuvette); Rate A (i.e., slope of total ATPase activity), 80 -280 s; Rate B (i.e., slope of ouabain-resistant ATPase activity), 400 -600 s. The difference between the two slopes is proportional to the Na
For the estimation of total, between-day, between-run, within-day, and within-run CVs, two measurements per specimen per assay and two assays per day from the aliquots were done for 20 days [4] . In the range of 1.7-41.5 mU, the curve of NADH oxidation was linear during the measured intervals (r ϭ 0.98). The activities changed proportionally with increasing protein concentrations (y ϭ 50.6x, r ϭ 0.99). The calculated CVs are presented in Table 1 . The detection limit (mean Ϯ 3 SD of spontaneous NADH oxidation) was 0.16 mU.
For the determination of healthy reference intervals, ghosts were prepared from 100 L of heparinized blood samples taken from 53 neonates, 93 children of different ages (1-18 years), and 42 adults. The study was approved by the Institutional Ethical Committee.
The enzyme activities are lower in children (P Ͻ0. [5] , who also reported decreased enzyme activities in children. Moreover, in spite of the difference of the methods used, our data are in the same range, as described [5] .
Our automated method has several advantages compared with the manual ones (e.g., low blood requirement, high precision, speed), so it might be a valuable tool for gathering data for the clinical importance of Na
This work was financially supported by Hungarian OTKA Grant T023845 and ETT Grant 182/97. Assessing the concentration of antinuclear antibodies (ANA) in a patient's serum is commonly done by the ANA-immunofluorescence assay (ANA-IFA) [1] [2] [3] [4] [5] [6] , a very tedious and subjective procedure. By contrast, ANA enzyme immunoassays (ANA-EIA) are easy to perform, and the results are not subjective. Although the performance of ANA-EIA was judged to be less than satisfactory [7] , five different ANA-EIA kits were recently proven to be comparable with ANA-IFA [8] . Similarly, in a recent study involving one of us [9] , a comparison of ROC curves for ANA-IFA and ANA-EIA showed equivalent performance. In this study we generated ROC curves with disease diagnosis as the gold standard and compared them with the ROC curves from the earlier study [10] . We also tested 98 serum samples from patients with primary Sjö gren syndrome (SS).
Comparison of Antinuclear Antibody Testing
The patients' serum samples entered into this study from the Arthritis Center of Nebraska (ACN) were part of the routine medical care when ANA-IFA was ordered. A total of 283 serum samples were collected from April 4, [11] . All of these samples were part of the daily laboratory routine, and none of the samples processed by the laboratory during this period was excluded. The 98 serum samples from patients diagnosed with primary SS had been stored frozen at the National Institute of Dental Research of the National Institutes of Health until needed for testing by ANA-EIA. Diagnosis of primary SS was made according to established criteria [12] . All information regarding ACN samples, which included ANA-IFA results, age, sex, diagnosis, and medications, was withheld until ANA-EIA results had been sent back to ACN. All information regarding primary SS samples was withheld until ANA-EIA results had been generated and sent back to NIH.
Samples from the ACN were tested by ANA-IFA (Kallestad Quantafluor; Sanofi Diagnostics Pasteur) according to the manufacturer's instructions. Samples from NIH were tested by ANA-IFA (ANA-HEp-2; ImmunoConcepts) according to the manufacturer's instructions. Samples were then stored frozen (Ϫ20°C) and shipped to Bio-Rad Labs., where they were tested by ANA-EIA with the automated analyzer Radias (Bio-Rad). The Radias instrument was programmed by the manufacturer to interpret ANA-EIA results of Ͻ0.9 as negative, 0.9 to 1.1 as indeterminate, and Ͼ1.1 as positive. The ANA-EIA plates for the Radias are coated with a HEp-2 cell extract containing ANA antigens, which include double-stranded DNA, SS antigen A (SS-A/Ro), SS antigen B (SS-B/La), Sm, ribonucleoprotein (RNP), Jo-1, and Scl-70.
Diagnostic sensitivity, specificity, positive predictive value, negative predictive value, and agreement were calculated with standard formulas [2] . These values were calculated after defining those diagnoses for which ANA is commonly used as a part of connective tissue disease (CTD) diagnosis as disease-positive. Hence, systemic lupus erythematosus, discoid lupus erythematosus, scleroderma/CREST (calcinosis, Raynaud phenomenon, esophageal motility abnormalities, sclerodactyly, and telangiectasia), Raynaud syndrome, SS, MCTD, overlap CTD syndromes, polymyositis, and dermatomyositis were considered disease-positive [11] and all other diagnoses were considered disease-negative. The exact McNemar statistic [10] was used to compare sensitivities and specificities. The 95% confidence intervals (CI) and ROC curves were constructed, and the areas under the curves were compared [13] .
Approximately 14% (39 of 283) of the ACN samples entered into this study were from patients diagnosed with a CTD. The most common diagnosis was systemic lupus erythematosus (n ϭ 16), followed by Raynaud syndrome (n ϭ 6), SS (n ϭ 6), scleroderma/CREST (n ϭ 5), MCTD (n ϭ 3), discoid lupus erythematosus (n ϭ 2), dermatomyositis/polymyositis (n ϭ 2), and an undefined CTD (n ϭ 9). Some of these patients were diagnosed with more than one CTD.
The area under the ROC curve for ANA-IFA (Fig. 1A ) was 0.804 (CI 0.758 -0.850) and did not differ significantly (P Ͼ0.05) from the area under the ROC curve for ANA-EIA, which was 0.817 (CI 0.772-0.862). The ROC curve for the ANA-IFA from this study did not differ significantly (P Ͼ0.05) from the ROC curves for the ANA-IFA in the previous study (Fig. 1B) .
With a reference range of Ͻ1:80 for the ANA-IFA, the sensitivity, specificity, positive predictive value, and negative predictive value were 64.1%, 80.7%, 34.7%, and 93.4%, respectively. With a reference range of Ͻ1.2 for the ANA-EIA, the sensitivity, specificity, positive predictive value, and negative predictive value were 71.8%, 76.2%, 32.6%, and 94.4%, respectively. Comparison of the sensitivity and specificity between the ANA-IFA with a reference range of Ͻ1:80 and the ANA-EIA with a reference range of Ͻ1.2 showed no significant difference (P Ͼ0.05).
When we tested the 98 serum samples from patients diagnosed with primary SS with a reference range for ANA-IFA of Ͻ1:80 and a reference range of Ͻ0.9 for ANA-EIA, 6 samples were commonly called negative and Fig. 1 . ROC curves for ANA-EIA ACN and ANA-IFA ACN (from this study with samples from the ACN) (A) and ROC curves for ANA-IFA ACN, ANA-IFA USCF1 (for the overall period), and ANA-IFA UCSF2 (for the common period) (ROC curves from Gniewek et al. [9] reproduced with permission) (B).
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Technical Briefs reference ranges, the difference between the sensitivity for ANA-IFA (88.8%) and ANA-EIA (92.9%) was not significant (P Ͼ0.05). The agreement between the two methods was 93.9%.
Some bias may have been introduced into this study because the ANA-IFA results were used by the physicians to establish diagnoses whereas the ANA-EIA results were not made available to the physicians. Although it may be reasonable to assume that this bias favored the ANA-IFA, it would be difficult to determine the extent of this bias because no definitive test for CTD exists.
Although information on patterns is lost with the ANA-EIA method, this may be a minor disadvantage. The ANA-IFA fluorescent patterns have been associated with certain clinical states [1] [2] [3] [4] [5] [6] , but no matter how convincing such associations may seem, they are difficult to confirm when unselected patients are used [14] . The earlier study [9] reported that only 3 of 8 patients with anticentromere antibody had a diagnosis of CREST syndrome, and only 1 of 19 patients with nucleolar antibody had a diagnosis of scleroderma. In this study, 2 of 4 patients with anticentromere antibody had a diagnosis of CREST, and none of the 4 patients with nucleolar antibody had a diagnosis of scleroderma. Although the association of certain patterns with certain clinical states has been reported, the incidence of these patterns in non-CTD clinical states has not been investigated thoroughly.
We conclude that the ANA-EIA method is equivalent to the ANA-IFA in screening for ANA in serum from patients with CTD. Differences in performance between the ANA-EIA and ANA-IFA may be insignificant when the appropriate cutoffs are selected. The appropriate cutoff may depend on many factors including the cost of false negatives and false positives as well as the prevalence of CTD. The ANA-EIA has the advantage of being easy to use, and the results are objective. This study was supported by Bio-Rad Laboratories, the Arthritis Center of Nebraska, and the National Institutes of Health. In 1992, an automated whole-blood microparticle enzyme immunoassay was developed (Abbott Labs.) for the measurement of tacrolimus concentrations (TAC I) on the IMx analyzer [1] . This method involves the antitacrolimus monoclonal antibody developed by Fujisawa Pharmaceutical, the company producing the immunosuppressant tacrolimus [2] . The assay requires 100 L of whole blood, and 24 samples can be analyzed in ϳ40 min after a rapid organic extraction (200 L of precipitation reagent: ZnSO 4 solution in methanol and ethylene glycol). The capture reagent consists of latex microparticles to which tacrolimus antibodies are attached, the enzyme is tacrolimusconjugated alkaline phosphatase, and the substrate is 4-methylumbelliferyl phosphate. This method yields CVs of ϳ10% (11.8% and 9.6% at concentrations of 15 and 25 g/L, respectively) [1] , but is limited by the detection limit of 5 g/L. Because in current clinical practice a nonnegligible percentage of transplant patients display low tacrolimus concentrations (Ͻ6 g/L), the immunoassay has recently been modified. A new assay, IMx tacrolimus II (TAC II), with a lower detection limit, has been developed, requiring 150 L of whole blood and 150 L of precipitation reagent. Whereas the TAC I has a dynamic range of quantification from 5 to 60 g/L, the TAC II assay has a range from 1 to 30 g/L, better corresponding to the therapeutic range of tacrolimus (5-15 g/L) [3] . Because this new assay will replace the TAC I, we have evaluated and compared the two assays in terms of their analytical performances, and their correlation in clinical Clinical Chemistry 43, No. 10, 1997 blood specimens obtained from kidney and liver transplant patients.
IMx Tacrolimus II vs IMx Tacrolimus Microparticle Enzyme Immunoassay Evaluated in Renal and
Analytical performances were evaluated on the same IMx analyzer, by the same technician, and on the same days. The pipettes used were calibrated before the study. All the analyses (mode 1 calibrator, controls, and patients' samples) in the study were run in duplicate, and blood samples after pretreatment were vortex-mixed individually for 10 s according to the manufacturer's instructions.
Each of the three controls [target concentrations low (L), medium (M), and high (H): 15, 25, and 40 g/L, respectively, for the TAC I; and 5, 11, and 22 g/L for the TAC II)] was used in replicates of 20 during three consecutive days. The within-run precision overall results were similar for the two assays (Table 1) . Mean values for the TAC I controls were 14.3, 23.9, and 38 g/L with CVs of 6.2%, 5.7%, and 5.2%, respectively. The corresponding values for the new assay were 5.4, 12, and 23.7 g/L with CVs of 7.1%, 6.7%, and 6.7%. In addition, to assess the betweenrun precision, each of the three controls was analyzed in replicates of two during 10 consecutive days. Mean values for the TAC I assay were 13.7, 23.7, and 40.5 g/L with CVs of 7.3%, 5.1%, and 7.1%, respectively. Comparative results for TAC II were 4.9, 10.7, and 23.1 g/L with CVs of 10.0%, 5.0%, and 7.2%, respectively. The detection limit of both assays has been evaluated by two approaches: first, by testing 10 samples of calibrator A (0 g/L), and second, by testing 10 tacrolimus-free clinical specimens (transplant patients under another immunosuppressive scheme). The limits of detection of TAC I, defined as the lowest concentrations that can be distinguished from zero with 95% confidence (mean ϩ 2 SD), were 3.8 and 6.4 g/L for the first and second approaches, respectively, and the corresponding results for the TAC II assay were 0.8 and 1.16 g/L, respectively. These results confirm the detection limit of ϳ5 g/L for the TAC I assay as described by Abbott, and suggest for the new assay a detection limit of ϳ1 g/L. To compare the two calibration curves, TAC I controls L and M (15 and 25 g/L) have been measured in triplicate on the TAC II assay, resulting in similar mean concentrations (14.2 and 25.4 g/L, respectively).
Correlation between the TAC I assay and the new TAC II assay in clinical practice has been evaluated with 70 whole-blood EDTA specimens obtained from kidney and hepatic transplant patients treated with tacrolimus. All samples were analyzed with quality-control material within a week. Samples with concentrations Ͻ5 g/L (n ϭ 9) have been excluded from the comparison study. With TAC I and TAC II data reported in the x-and y-axes respectively, the correlation coefficient was 0.960 and the regression equation was y ϭ 0.81x ϩ 0.50. Thus TAC II results were lower than those from TAC I by 9 -17% in concentrations of 5-30 g/L (according to the equation). To illustrate this bias, a Bland-Altman plot for method comparison is shown in Fig. 1 [4] . In this graph, the differences between the assays are plotted against the averages of the two methods. Horizontal lines represent the mean difference (1.26 g/L) and mean difference plus or minus 2 SD (mean Ϯ 2.63 g/L).
Analysis of the data based on the organ transplanted (n ϭ 30 for liver, n ϭ 31 for kidney) produced no significant changes in the correlation coefficient. The slope for the hepatic transplant samples was 0.73 and the y-axis intercept was 1.0, but the difference was not statistically significant. The positive intercept value compensates partly for the low slope, resulting in similar concentrations in the lower range. During these clinical sample analyses, three control samples were simultaneously added. Mean (n ϭ 10) low, medium, and high concentrations were: 14.0, 25.3, 42.0 mg/L and 5.2, 11.3, 24.3 mg/L for TAC I and TAC II, respectively, similar to the values obtained in the precision study, thus confirming the absence of shift in the curves over time. In addition, three blood specimens (A16, B16, C16) from the tacrolimus European quality-assessment scheme organized by D. Holt, London, UK, were analyzed by both techniques. A16 and C16 are aliquots of tacrolimus-free blood to which 20 and 40 g/L tacrolimus have been added, and B16 is an aliquot of a single pool of blood samples from transplant patients, presenting a consensus mean of tacrolimus concentration of 13.8 g/L. The results obtained in our laboratory with both assays are: 23.1, 47.8, and 14.8 Table 1 . Performances of IMx tacrolimus I assay (TAC I) compared with the new IMx tacrolimus II assay (TAC II).
Low control
Medium control High control The reliability of the new TAC II assay is based on good reproducibility (similar within-run and betweenrun CVs to TAC I), obtained in a concentration range much lower than previously possible. This improvement clearly better corresponds to the current dosage regimen of tacrolimus. The new assay has a detection limit of 1 g/L, which is similar to that obtained from ELISA [3, 5] . In addition, during our evaluation, the new assay presented an excellent stability of the calibration curve. The first calibration of TAC II obtained in September 1996 was still valid 4 months later, whereas the TAC I assay was recalibrated two times during the same period of time. The observation of tacrolimus concentrations significantly lower with the new assay appears slightly surprising since both assays use the same monoclonal antibody. A possible explanation could be the different volume of blood and precipitation reagent involved in the assays. Some coprecipitation or drug trapping in the protein clot might occur in the TAC II, mainly with fresh blood samples and less with pretreated and hemolyzed samples as controls. This would be consistent with the need of agitation duration of at least 10 s for TAC II (150 L of blood ϩ 150 L of precipitation reagent) to avoid incomplete breakup of the erythrocytes. Such need was less critical for TAC I (100 L of blood ϩ 200 L of precipitation reagent). Owing to the higher proportion of solvent used in the TAC I assay, a higher extraction ratio of some tacrolimus metabolites could also contribute to a higher result as compared with the new assay. This would also explain why control samples produce data closer to expected values and to TAC I values than do patients' samples. Nevertheless, taking into consideration the clinical practice of tacrolimus therapeutic monitoring, the new IMx tacrolimus II assay, with the improved sensitivity, should meet the need of most users.
We acknowledge the collaboration with C. Lhoëst and B. Herzig-Moter from Abbott Diagnostics, and the technical skill of C. Luypaert. Oxidative stress resulting from increased free-radical production and (or) defects in antioxidant defenses is implicated in the pathogenesis of several diseases [1] . Biological effects of these highly reactive compounds are controlled in vivo by a wide spectrum of antioxidant mechanisms. Among these, the enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPX) act as endogenous antioxidants [2] . Introducing SOD and GPX Clinical Chemistry 43, No. 10, 1997 measurements in laboratory medicine application requires identification of the biological sources of variation for: assessing the desired performance characteristics of a test, deriving the utility of the conventional populationbased reference interval, and defining significant differences that imply changes in serial results from an individual [3] .
Biological Variation of Superoxide
Our study was designed to estimate biological variation components of SOD in erythrocytes and GPX in whole blood to examine the role of these enzymes in the diagnosis, screening, and monitoring of patients.
Eighteen healthy individuals (8 men and 10 women) between 24 and 48 years of age were included in the study. They agreed to maintain uniform daily habits during the study. Venous blood samples were collected into lithium heparinized tubes once a week, between 0800 and 0900 h, for 5 consecutive weeks. Specimens were drawn from the volunteers after 20 min in a sitting position. Owing to the short time stability of the samples, their analyses were performed on the day of collection.
Analytical procedures: SOD activity in erythrocytes was measured by the rate of inhibition of 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride (INT) reduction (Ransod SD 125, Randox Lab.) and expressed in U/g of hemoglobin (Hb). GPX activity in whole blood was measured by a modification of the method of Paglia and Valentine [4] (Ransel RS 505, Randox Lab.) and expressed in U/L. Enzyme activities were measured in a Cobas Mira Plus analyzer (Hoffmann-La Roche) at 37°C. Hb concentration was determined with a Sysmex K1000 hematological analyzer (Toa Electronics). An internal control system based on commercial lyophilized blood (Ransod control SD 126 and Ransel control SC 692, Randox Lab.) was used for validation of analytical runs.
Analytical between-run imprecision was determined from 20 day-to-day measurements of control samples and expressed as CV ab . Before analyzing the data to establish biological variation, the Cochran test [5] and the Reed test [6] were used to exclude outlying values. From the samples, 2 of 180 values for SOD and 2 of 180 values for GPX were ruled out. One individual was ruled out when the Reed test was applied to the GPX set of data. The index of heterogeneity [3] and the Levene test [7] were applied to check the homogeneity of variances. Two individuals were ruled out according to the Levene test.
Biological within-subject (intraindividual) variation (CV i ) was estimated from the total within-subject variance (intraindividual plus analytical) minus between-run analytical variance [3] with the formula:
The term (s 2 iϩa ) was computed by averaging data from all volunteers (⌺s 2 iϩa /n). The between-subject (global) biological variation (CV g ) was obtained [3] with the formula:
where s 2 t is the total variance. Other quantities were calculated as follows:
Index of individuality (II) as the ratio:
Critical differences for serial results (CD) (P Ͻ0.05) [3] , applying the formula:
Desirable quality specifications for analytical imprecision (CV D ) according to the following expression [8] :
After logarithmic transformation to normalize the data, Student's t-test was applied to examine differences between sexes, and regression analysis and correlation performed between the two enzyme activities in the volunteers' samples.
A slight but statistically significant positive correlation was found between SOD in erythrocytes and GPX in total blood (r ϭ 0.301, P ϭ 0.0001). Between-run imprecision (CV ab ) was 6.12% for SOD and 6.57% for GPX. Desired quality specifications for imprecision were 6.19% for SOD analysis in erythrocytes and 3.86% for GPX analysis in whole blood. Bias was 3.36% and 5.75% for SOD and GPX, respectively. Table 1 shows biological variation components and data derived from them in both sexes and in the whole population.
The positive correlation found between SOD in erythrocytes and GPX in whole blood appears logical since GPX is, together with catalase, one of the enzymes that destroys the H 2 O 2 generated by SOD action [2] . The analytical between-run CV ab accounts for 25.73% of the total variation (analytical plus biological) for SOD and 18.52% for GPX. These percentages are similar to those obtained for other enzymes with well-established biological variation estimates in studies where volunteer data were obtained in the same run [9] . These results support that estimation of biological variation components with different lots does not substantially affect reliability of the information obtained.
The lower total biological variation (CV i ϩ CV g ) suggests than SOD is less sensitive to environmental or physiological changes than GPX. CV i of SOD and GPX was similar and comparable with those obtained for other enzymes such as serum alkaline phosphatase, amylase, or aspartate aminotransferase and lower than those obtained for serum ␥-glutamyltransferase or creatine kinase [10] . CV i for SOD in erythrocytes obtained in the women' s group (12.8%) lay between the two values reported by Gallagher et al. (17.5% in free diet, and 10.91% in controlled diet) [11] , who studied SOD activity in serum of five healthy females in the same time span evaluated here. The lower CV i for SOD in erythrocytes obtained in this
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Technical Briefs study in non-diet-controlled women could be explained by the homogeneity of data in a higher number of participants.
We applied the index of heterogeneity (IH) in the whole set of data, and values obtained were clearly lower than the critical value 1.45 [12] , indicating homogeneity between within-subject variances. However, observation of the individual CV i revealed that some volunteers showed discrepant values compared with the global set of data. The Levene test was therefore applied and two individuals subseqently had to be ruled out. Thus, IH is not applicable in our set of data to establish homogeneity of variances.
II is considered to be the key for determining the practical utility of population-based reference ranges. If Ͻ0.6, the use of a reference interval is of little value for diagnostic purposes. If it is Ͼ1.4, then the reference interval is valuable [3] . II for GPX was 0.45, suggesting that it has little value as a diagnostic or screening tool. The differences in SOD II between sexes are principally related to the differences in SOD between-subject variation. At present, possible causes (influence of life-style or hormonal status) for these sex differences remain unknown.
To our knowledge, this is the first report on the biological variation of GPX in whole blood and SOD in erythrocytes. Data obtained from the biological variation of these enzymes support SOD in erythrocytes as the scavenger enzyme of choice for diagnosis of an alteration in antioxidant status in a pathological situation, as well as for screening in population studies. In view of its strong individuality and smaller critical differences compared with SOD, GPX determination in total blood would be useful for monitoring antioxidant status in pathological situations and changes in life-style such as diet or exercise. Improvement in measurement of GPX in blood is required to achieve the analytical goal established in this work.
We thank Joan Vila and Jordi Sunyer for their assessment in statistical analyses and Christine O'Hara for the English revision of the manuscript. This work was supported in part by grant from the CIRIT (1995/SGR/ 00167). conditions. Many kinds of denitrifying bacteria have been isolated from the human oral cavity, upper respiratory tract, and alimentary tract (e.g.) [1] [2] [3] [4] , including pathogens of Pseudomonas, Neisseria, and Campylobacter. Taking these studies into consideration, it is proper to assume that the concentrations of N 2 O in exhaled air exceed those in the atmosphere, although no studies have been published related to N 2 O in exhaled air. The purpose of this study is to establish an analytical method for detection of N 2 O in exhaled air by using gas chromatography (GC) and infrared-photoacoustic spectrometry (IR-PAS) [5] . Exhaled air samples were collected from 15 healthy subjects, ages 20 -60 years. Each subject was fully informed of the experimental procedures before giving consent. Samples were collected with a commercially available breath collection system (a 750-mL gas sampler from Quintron, Milwaukee, WI). The exhalation procedure was as follows: Subjects were to inhale deeply but not to maximum capacity, hold the inhalation for ϳ5 s, and then exhale into the sampling bag. This procedure was repeated twice for all subjects. The protocol was approved by the Human Research Committee of the Research Center of Health, Physical Fitness, and Sports of Nagoya University.
Measuring Nitrous Oxide in Exhaled Air by Gas
The exhaled air sample was analyzed within 90 min of collection, because preliminary studies showed that leakage from the sampling bags was negligible over a 2-h period. Emission of N 2 O was taken as the difference in the concentration between the sample and the room air.
A gas chromatograph (Type GC-14BPE; Shimadzu) equipped with an autosampler, PoraPak (Q 80/100 mesh 1.0 m) columns, and a 63 Ni electron capture detector was used for the GC determinations of N 2 O concentrations. Methane, at 48. 5 mL/L in argon, was used as a carrier gas at a flow rate of 40 mL/min. The oven, columns, and detector temperatures were regulated at 60°C, 100°C, and 300°C, respectively. Calibration was with a gas of 3.1 L/L N 2 O in nitrogen (Nihon Sanso Co., Japan).
A MultiGas Monitor (Type 1302; Brü el & Kjaer, Denmark) equipped with an optical filter (UA0985, 2215 cm Ϫ1 ) was also used to determine N 2 O concentrations. The high humidity and carbon dioxide content (ϳ40 mL/L) in exhaled air posed a problem, because these interfered with infrared absorption of N 2 O. To remove this interference, sample gas was passed though a 5 cm ϫ 30 cm pipe containing 2-mm-diameter soda lime granules and a 5 cm ϫ 5 cm pipe containing 2-4-mm-diameter alumina granules in series before the analyzer. The calibration curve was constructed from analyses of pure nitrogen gas (grade S), the calibration gas (at 3.1 and 10.5 L/L), and various dilutions of these (final concentrations 1.1, 1.7, 2.1, and 5.3 L/L). The calibration curve shown in Fig. 1 (top) reveals good linearity for this range.
We found N 2 O in exhaled air from all subjects, at concentrations ranging from 60 to 890 nL/L by IR-PAS and from 30 to 730 nL/L by GC. Fig. 1 (bottom) shows the highly linear relationship between the values found by GC and IR-PAS (r ϭ 0.985, P Ͻ0.001) and a systematic error of ϳ10%. A possible cause of this difference is the slight absorption of N 2 O in the CO 2 /H 2 O trap. N 2 O is usually analyzed by GC with electron capture detection for analyses in the range of ppb (nL/L). Because N 2 O has Ͼ200 potent infrared absorption bands compared with CO 2 , one can detect such a low concentration of N 2 O by IR-PAS with almost the same accuracy as GC. The analytical time required for one sample by GC is ϳ12 min, whereas IR-PAS takes Ͻ2 min. In addition, a gas chromatograph equipped with an electron capture detector contains radioisotope ( 63 Ni), so the use of the apparatus is restricted for space. For these reasons, the IR-PAS device is practical enough for measuring N 2 O at concentrations in the range of Ͻ1 L/L in exhaled air if used with a suitable trap for CO 2 /H 2 O. Aldosterone, a steroid hormone secreted by the adrenal cortex, is important in the overall control of sodium and potassium balance. Abnormalities in aldosterone concentrations are seen in a variety of clinical conditions. Overproduction (hyperaldosteronism) may result both from a primary cause such as adrenal adenoma [1] or a secondary cause, e.g., stimulation by increased renin release [2] . Underproduction of the hormone is seen in such diseases as Addison disease [3] .
Many methods for measurement of plasma aldosterone have been based on the extraction method of James and Wilson [4] . However, technical progress has enabled the production of direct kit methods for measuring plasma aldosterone. Previous studies [5, 6] have demonstrated that direct methods gave anomalous results in certain circumstances, possibly because of the presence of polar metabolites. The purpose of the current study was to compare a direct method with an existing extraction method for measuring aldosterone-first, in a large number of samples from clinical sources, and second, after physiological alterations of sodium intake.
Plasma was obtained in the morning from 89 individuals after they had sat for 5-10 min: 40 patients with essential hypertension, average age 52 years (range 25-80 years; 21 men, 19 women); 28 presumed healthy volunteers, average age 45 years (range 24 -77 years; 19 men, 9 women); 17 patients with chronic renal failure (serum creatinine 349 Ϯ 32.2; range 189 -535 mol/L), average age 59 years (range 29 -83 years; 9 men, 8 women); a 42-year-old woman with a pheochromocytoma; 2 patients with Conn syndrome (a 37-year-old woman and a 35-year-old man); and a 75-year-old woman with persistent hypertension and hypokalemia. Except for the chronic renal failure patients, none of the subjects had any sign of renal failure as determined by serum creatinine values (all Ͻ110 mol/L). In addition, two or three quality-control pools were analyzed in duplicate in each assay run.
We also determined the effect of sodium alteration on the measurement of plasma aldosterone concentrations in 8 hypertensive individuals (4 women, 4 men). Measurements were made after 1 month on a low-sodium diet and 1 month on a high-sodium diet in a double-blind, crossedover, randomized designed study.
Blood samples (10 mL) for the plasma aldosterone determinations were obtained from a subcutaneous vein in the forearm; collected into lithium-heparin tubes, the samples were immediately centrifuged at 1200g for 15 min at 4°C. The plasma was removed and stored at Ϫ20°C until assay. Blood was also taken for routine biochemical determinations. Urine samples (24 h) were collected for the measurement of sodium and creatinine. Blood pressure recordings were made with an ultrasound sphygmomanometer (Arteriosonde; Roche). Ethical approval was obtained from our institution.
The extraction-based method for RIA of plasma aldosterone was based on that of James and Wilson [4] . In brief, plasma samples (0.5 mL) were extracted with 10 mL of dichloromethane (BDH/Merck; AnalaR) to which had been added [ 3 H]aldosterone (Radiochemical Centre, Amersham), 1000 counts/min, to assess the recovery of the process for each sample. The aqueous phase was dried under air and the extracts were reconstituted in 500 L of phosphate-buffered saline (PBS; NaH 2 PO 4 ⅐ 2H 2 O 7.5 mmol/L, anhydrous Na 2 HPO 4 32.4 mmol/L, NaCl 103 mmol/L, sodium azide 15.4 mmol/L, bovine serum albumin 2 g/L). The reconstituted samples were then assayed by RIA, 100-L samples being placed, in duplicate, into assay tubes. Additionally, 100 L of sample was placed into scintillation vials to which was added 4.5 mL of scintillation fluid (Ultima-gold; Packard) to assess recovery. To the assay tubes was added 100 L of diluted antiserum (obtained from St. Mary's Hospital, Paddington, UK) and 100 L of 125 I-labeled aldosterone (Amersham) that had been diluted in PBS to 2000 counts/min. The maximum binding was 76.0% Ϯ 0.9% (n ϭ 85). A 9-point calibration curve covering the range 0 -160 pg/ tube (0 -4440 pmol/L) was prepared from dilutions of aldosterone (Sigma) in PBS. The effective limit of detection of the assay was given as equivalent to the lowestconcentration calibrator [1.25 pg/tube (35 pmol/L)]. The bound and unbound fractions were separated by adding 1 mL of cold dextran-coated charcoal [250 mg of activated charcoal (Sigma) and 25 mg of dextran T-70 (Pharmacia) in 100 mL of PBS] to the tubes. After 5 min the samples were centrifuged at 1200g for 15 min at 4°C, and the radioactivity in the bound fractions was counted in a gamma counter (1261 Multigamma; Wallac) for 5 min.
The extracted values were all corrected for recovery.
To measure aldosterone by a direct method, we used a Coat-A-Count kit (DPL Division, Euro/DPC), according to the manufacturer's instruction. Plasma (200 L) was placed into antibody-coated tubes, to which was then added 1 mL of 125 I-labeled aldosterone. The samples were mixed and incubated at 37°C for 3 h before being decanted and counted for radioactivity in the gamma counter for 1 min. A 7-point calibration curve was constructed from the reconstituted calibrators provided with the kit (0 to 3300 pmol/L) and treated similarly. The Clinical Chemistry 43, No. 10, 1997 minimal detectable limit for this assay as given by the manufacturer is 44 pmol/L.
Group comparisons were performed by using Student's paired t-tests. Group results are expressed as means Ϯ SE. Method comparisons were carried out by linear least squares. P Ͻ0.05 was taken to be significant.
Plasma aldosterone determined by the direct method in 40 essential hypertensive individuals-blood pressures of 166.8 Ϯ 3.4/99.0 Ϯ 1.9 mmHg (reclining systolic/reclining diastolic)-was not significantly different from that determined by the extraction method: 610.3 Ϯ 48.8 vs 607.8 Ϯ 54.2 pmol/L, respectively. Likewise, results for the 28 volunteers (blood pressure 121.3 Ϯ 2.5/75.0 Ϯ 1.4 mmHg) showed no significant difference between the direct method (462.5 Ϯ 41.4 pmol/L) and the extraction method (432.6 Ϯ 39.5 pmol/L). A plot of all the measured values is shown in Fig. 1 . Samples from two subjects gave values below the assay detection limits and were therefore excluded from the analysis. Linear regression analysis revealed a combined correlation coefficient for all the subjects of 0.91 (n ϭ 83) and a best-fit line equation of y ϭ (1.14 Ϯ 0.06)x ϩ (Ϫ9.22 Ϯ 42.52). However, further analysis of the 17 patients with chronic renal failure (creatinine clearance 27.6 Ϯ 4.7 mL/min) showed that, although the correlation between the two methods was good (r ϭ 0.96) with a regression line of y ϭ (1.26 Ϯ 0.10)x ϩ(91.96 Ϯ 108.3), the mean value obtained with the direct method (1154 Ϯ 221 pmol/L) was significantly higher than that obtained with the extraction assay (842.0 Ϯ 168 pmol/L; P ϭ 0.001; Fig. 1 ). On average, concentrations measured in the patients with chronic renal failure were 36.7% Ϯ 7.0% higher by the direct method. However, there was no association between the difference in values, expressed as a percentage of the extracted value, and the degree of renal failure, as measured by creatinine clearance (r ϭ 0.06; ns).
Additional analysis of the comparisons between the two assays for the 12 individuals whose aldosterone was Ͻ300 pmol/L revealed no significant difference (P ϭ 0.15) between the mean reported by the direct method (232.8 Ϯ 14.6 pmol/L) and that by the extraction assay (196.6 Ϯ 19.6 pmol/L).
The patient with pheochromocytoma had a plasma aldosterone of 1267 pmol/L as determined by the direct method and 1492 pmol/L by the extraction method. The two patients with Conn syndrome had similar results on both assays: 2662 vs 2812 pmol/L and 1539 vs 1716 pmol/L. The aldosterone concentration in the patient with persistent hypertension and hypokalemia was extremely high: The undiluted sample value obtained with the direct method was 8834 pmol/L and that determined by the extraction method was 7025 pmol/L.
Although urinary sodium during the low-salt diet (70.3 Ϯ 13 mmol/24 h) was significantly different from that during the high-salt diet (159.9 Ϯ 22.8 mmol/24 h; P Ͻ0.001), the plasma aldosterone concentration as determined by the extraction method (636.1 Ϯ 96.6 pmol/L) on the low-salt diet was not significantly different from that determined by the direct method (618.9.3 Ϯ 12.9 pmol/L). The values determined on the high-salt diet by both methods were also comparable (476.3 Ϯ 58.7 vs 458.3 Ϯ 77.1 pmol/L).
Regarding analyses of the quality-control pools, the mean value obtained for the high-concentration pool by the direct method (2724.3 Ϯ 44.8 pmol/L; n ϭ 50; CV 11.6%) was not significantly different from that measured by the extraction method (2721.7 Ϯ 57.9 pmol/L; n ϭ 50; CV 15%). Similarly, there was no significant difference between the normal pool value obtained by the direct method (697.2 Ϯ 12.1 pmol/L; n ϭ 50; CV 12.3%) or by the extracted method (709.9 Ϯ 14.0 pmol/L; n ϭ 50; CV 13.9%). The same was true for the low-concentration pool mean: direct assay 143.2 Ϯ 6.1 pmol/L (n ϭ 16; CV 17.0%), extraction method 142.8 Ϯ 5.3 pmol/L (n ϭ 50; CV 26.1%).
Compared with the extraction method, the Coat-ACount RIA kit measures plasma aldosterone directly and is technically easier to perform. The kit allows for a greater number of samples to be processed in an assay, is far less time-consuming, and is cost effective. The CVs for the pooled samples were similar in both methods. Results from these two methods in normotensive and hypertensive individuals were close to the line of identity (see Fig.  1 ). The two methods also yielded comparable results during physiological alterations in circulating aldosterone as induced by dietary sodium alteration. However, in chronic renal failure patients, although the correlation between the two methods was good (r ϭ 0.96; n ϭ 17), the results obtained by the direct method were significantly higher, on average 36.7% Ϯ 7.0%, than those obtained with the extraction method-possibly resulting from the accumulation of polar metabolites in patients with renal failure [5] . Our study, in conjunction with previous work [5, 6] , highlights the problem of using direct kits to assay plasma from patients with chronic renal failure, which may overestimate the plasma aldosterone. In these pa- Cigarette smoking is a dominant risk factor for atherosclerotic vascular disease. Moderate increase of plasma homocysteine (Hcy) is also associated with various forms of vascular disease [1] . Several genetic and nutritional factors, which interact in a complex manner, determine the concentration of plasma Hcy. On theoretical grounds one would suspect an indirect effect of smoking on Hcy metabolism, mediated by the effects on the cofactors for Hcy metabolism, vitamin B 12 , B 6 , and folate [2, 3] . In a previous report we found current smoking to be associated with moderately increased Hcy in patients with premature peripheral atherosclerosis but not in control subjects [4] .
Several mechanisms involving pro-oxidant properties, e.g., redox changes in glutathione, can explain why smoking contributes to atherosclerotic vascular disease [5, 6] . Because of a previously found correlation with redox status of thiols related to glutathione [8] , we hypothesized that smoking could interfere with the redox status of these thiols.
In the present pilot study we used a newly developed method [9] to investigate the redox status of plasma Hcy and related aminothiols in healthy young subjects, differing in current smoking habits. Possible interactions between smoking habits and cofactors for Hcy metabolism were also analyzed.
All 41 subjects-19 women and 22 men, mean age 26 years (range 20 -33)-had completed a health declaration, and those with signs of cardiovascular disease had been excluded. Nineteen were nonsmokers and 22 current smokers. A nonsmoker was defined as a person who had never smoked or who had not smoked for at least 1 year. Current smokers consumed at least 10 cigarettes/day and had done so for at least 2 years; they were told not to change their daily smoking habits during the study. The following factors were recorded: smoking habits, length, weight, history of cardiovascular disease, medication, last menstruation, and previous medical admissions.
Blood samples were taken in the morning after an overnight fast and analyzed with the following laboratory tests: hemoglobin, erythrocyte count, platelet count, leukocyte count, total cholesterol, triglycerides, HDL-cholesterol, and apolipoproteins A-I and B. LDL values were derived from the Friedewald formula. Serum cobalamin and serum folate were measured by the Simultrac-SNB Radioassay Kit (Becton Dickinson). Vitamin B 6 was measured as its first active metabolite, pyridoxal 5-phosphate, by an enzymatic method [10] .
For thiol analysis, we analyzed blood collected into 3 evacuated tubes containing either monobromobimane or N-ethylmaleimide as thiol-derivatizing reagents or no derivatizing additive. The blood was centrifuged at 10 000g for 1 min at room temperature. Analysis of the plasma from blood collected in monobromobimane solution yielded the amounts of reduced thiols; analysis of plasma from blood collected in N-ethylmaleimide gave the amounts of the oxidized forms; and the total amount of thiol components was assayed in the untreated plasma. The protein-bound fraction was calculated by subtracting the reduced and free oxidized species from the total amount. The total, protein-bound, reduced, and oxidized forms of Hcy, cysteine, and cysteinylglycine (a degradation product of glutathione) are reported in Table 1 . A more extensive description of the method is given by Mansoor et al. [9] .
Differences between groups were tested with Wilcoxon's two-sample tests. Multiple linear regression analysis and multiple logistic regression analysis were performed with JMP software (SAS Institute). Mean values were determined for each sex and for smokers and nonsmokers. Univariate analysis for differences between smokers and nonsmokers were made within each sex. We found no significant differences in basic and hematological characteristics between the groups except that male smokers had a lower weight and higher concentrations of apo A-I.
As shown in Table 1 , no fraction other than reduced Hcy differed between smokers and nonsmokers; also, the young men had higher total Hcy concentrations than the young women. The distribution of reduced Hcy among male and female smokers and nonsmokers is shown in Fig. 1 . The concentrations of the various cofactors for Hcy metabolism showed no significant differences between smokers and nonsmokers.
Multiple regression analysis with the reduced fraction of Hcy as responder revealed that no other factors signifClinical Chemistry 43, No. 10, 1997 icantly influenced the association between current smoking and the concentration of reduced Hcy, but vitamin B 6 was noted to have an effect on reduced Hcy among nonsmokers, both in univariate and multiple regression analysis. A substantial part of this finding, however, depended on one outlier, which was from the only nonsmoker with a high concentration of reduced Hcy. Notably, she had a very low value for pyridoxal phosphate (vitamin B 6 ), the next to lowest value for total Hcy, and the highest serum folate content. Multiple logistic regression analysis with smoking habit as responder suggested that only reduced Hcy and triglycerides were significant discriminators.
A recent study on Hcy and other risk factors for vascular disease in 3000 healthy individuals demonstrated a positive correlation between current smoking and total Hcy [15] . This association is thought to be caused by the effects of smoking on the cofactors for Hcy metabolism: vitamins B 6 , B 12 , and folate [2, 3] . The present study, however, does not demonstrate a difference in total Hcy between smokers and nonsmokers-possibly because of the relatively small number of subjects or their youth. Nonetheless, the difference in reduced Hcy is clear and independent of gender or registered covariates of smoking, except for a negative correlation between vitamin B 6 and reduced Hcy in nonsmokers.
Two major different mechanisms could be of importance for the association of smoking and increased concentrations of reduced Hcy. One is displacement of disulfide-bound homocyst(e)ine in plasma by compounds in the cigarette smoke. The other is extracellular export of reduced Hcy as a defense reaction against oxidative stress by cigarette smoke. If displacement is important, it should probably influence the redox status of other thiols as well.
Similar results, with even higher concentrations of reduced Hcy, but not increased total Hcy, are found in AIDS patients [16] , indicating a role of the immune system. In patients with homocystinuria, whose concentrations of Hcy are very high, the reduced fraction is relatively greater than in subjects with moderate hyperhomocysteinemia [7] . Previously, we demonstrated that the ratio between reduced and total Hcy correlates with the same ratio for cysteine in patients with premature peripheral atherosclerotic disease [8] . This correlation was 
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Technical Briefs not seen in the present study (data not shown). An explanation for this discrepancy may be that smoking in some way might shift the equilibrium among thiols/ disufides/mixed disulfides in plasma [6] and that the present study involved only healthy subjects. The reduced fraction of Hcy is highly labile and prone to autoxidation of its sulfhydryl group. For this reason the reduced fraction of Hcy, representing only 1.3% and 2.9% of the total amount of Hcy in nonsmokers and smokers, respectively, is thought to be the metabolically most active fraction, whereas the stable oxidized fractions are more inert. Hultberg and colleagues [11] found that reduced Hcy was increased and total Hcy was decreased after administration of N-acetylcysteine (NAC), indicating a displacement effect of NAC on plasma fractions of Hcy. Other possible causes for the plasma compartment of reduced Hcy to be increased are related to intracellular free radical defense, e.g., cellular import of disulfide-Hcy or intracellular reduction of the disulfide bond. The latter mechanism involves scavenging of free radical-generated electrons and subsequent export from the intracellular compartment of the reduced Hcy [12] . Several explanations for the metabolic activity of reduced Hcy have been proposed. Reduced Hcy may cause redox cycling and disulfide interchange with other thiols, preferably cyst(e)ine, thus interfering with disulfide bonds. This mechanism may be important in protein folding and enzyme activation [8] .
The reasons why smoking causes a more than twofold increase of reduced Hcy in plasma cannot be settled from the present study. The many complex actions of cigarette smoking may be related to oxidizing components, e.g., oxygen free radicals, aldehydes, or NO 2 . Sulfhydryl groups in thiols have an important role in scavenging carbon radicals [13] , and sulfur radicals could also be formed by NO 2 from cigarette smoke and plasma thiols [14] .
The marked increase of the small fraction of reduced Hcy we found in young, healthy smoking subjects as compared with nonsmoking controls might be what contributes to the damaging effects of smoking.
Urine Organic Acid Profiling by Capillary Gas Chromatography After a Simple Sample Pretreatment, Petr Hušek (Inst. of Endocrinol., Národní Ave. 8, CZ-11694 Prague 1, Czech Republic; fax ϩ420-2-24905325, e-mail phusek@endo.lib.cas.cz) Organic acids occurring in physiological fluids comprise key metabolites of virtually all pathways of intermediary metabolism and may also be derived from exogenous sources. The urinary organic acids especially are considered as indicators of organic acidurias associated with various inherited and acquired disorders. A classical procedure for their profiling involves ethyl acetate extraction of acidified urine, oxime-trimethylsilyl derivatization of the dried extract, and capillary gas chromatography (GC) with or without mass spectrometry (MS) [1, 2] . A significant technological advance enables one to take advantage of a nonchromatographic tool of so-called tandem MS (MS-MS), which eliminates time-consuming separation techniques and reduces requirements for sample preparation to the extraction and derivatization of the analytes [3, 4] . However, the cost of the instrumentation currently is high.
Along with a marked progress in analytical instrumentation, new methods of sample pretreatment were developed in the last decades [5, 6] , although no substantial changes in the derivatization methodology were observed at this same time. A breakthrough in this respect might bring the discovery introduced by us in the 1990s [7] , i.e., that chloroformates were able to act as potent and rapid esterification-alkylation reagents of various classes of multifunctional carboxylic acids even in presence of water. When used for profiling of serum organic and (or) Clinical Chemistry 43, No. 10, 1997 amino acids, the sample pretreatment takes several minutes [8, 9] .
In this paper the same procedure used for plasma organic acid profiling [8] was used for working up urine samples. A pool of the first morning urine from five male controls (ages 24 to 52 years, approximate creatinine content of 8 mol/L) in an amount of 0.2 mL was supplemented with 20 L of 2-phenylbutyric acid used as an internal standard (IS) (1 mmol/L in acetonitrile-water, 1:1), 0.2 mL of ethanol, and 0.4 mL of acetonitrile. If a precipitate was formed during 10 -15 min of standing, it was subsequently centrifuged down at 2000g for 5 min. To remove amines and amino acids the medium was pushed through a bed of AG 50W-X8 cation exchange resin (100 -200 mesh, H ϩ form; ϳ25 mg) placed in a 1.5-mL pipette tip on a glass wool plug. Five-hundred microliters of the acidified eluent were then treated with 20 L of ethyl chloroformate and 40 L of pyridine in a silanized 2-mL screw vial and vortex-mixed for ϳ10 s. After the addition of 0.25 mL of dichloromethane and 0.5 mL of 1 mol/L aqueous solution of sodium bicarbonate-carbonate (2:1), the two-phase system was vortex-mixed again, and after reaching phase equilibrium, the upper phase was aspirated and the organic phase dried by adding sodium sulfate. The volume was subsequently reduced to 80 -100 L by nitrogen blowing at room temperature, and a 2-3-L aliquot was injected onto the column via hotneedle quasisplitless technique when the split-vent was A Shimadzu GC 14 gas chromatograph with flame ionization detector and a 0.25 m-PAS™ 1701 fused silica capillary 25 m ϫ 0.32 mm (Hewlett-Packard), programmed at 5°C/min in the range 60 -280°C (hold for 4 min), and injector and detector temperatures set at 250 and 300°C, was used for the analysis. Hydrogen was used as the gas phase at a head pressure of 50 kPa.
The corresponding chromatographic profiles are shown in Fig. 1 . Identification of the analytes was based on comparison of the retention times with those of calibrators; however, it does not mean that every one of the assigned peaks is a chemical individuum. The 2-phenylbutyric acid appeared to be a convenient IS because on the used stationary phase it was eluted in a vacant area of the chromatogram and because it was not found in human urine. The 1701 middle-polar phase was found to be the most effective in separating such a complex mixture of metabolites of all the phases tested (e.g., type 1, 5, or 17) and the PAS capillary of Hewlett-Packard was proven to be superior to those of other distributors. GC-MS studies should be performed to elucidate structure of the unidentified metabolites, and this would be the next task.
Within-run CVs did not differ too much from those resulting from the mere derivatization only, being Ͻ6% (n ϭ 10) for most of the analytes. Recovery of standard organic acids added to urine samples (n ϭ 10) was within 89 -112%.
It should be noted that to reach an optimum response without a higher amount of accompanying side products [8] , the high content of the two organic solvents (750 mL/L) in the reaction medium was justified with respect to a high abundance of lactic acid and the aliphatic oxo(mono) carboxylic acids in plasma. However, such a high portion of acetonitrile in the medium was found to prevent some di-and tricarboxylic acids from being esterified effectively; the same is true for the important glycine conjugates. Thus, an improved and more effective chemical treatment covering most of the metabolites is examined at present.
Nevertheless, the feasible access to urine metabolic profiling-by omitting the necessity for compound isolation and enabling derivatization in seconds-is, undoubtedly, worthy of more-comprehensive consecutive studies. Table 2 . Variations in serum, saliva, and urine concentrations of F and E (and in their ratios). Clinical Chemistry 43, No. 10, 1997 
